Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer

BACKGROUND: Prolonged infusion of low dose gemcitabine (PLDG) in combination with platinum has shown promising activity in terms of improved response rate and progression free survival (PFS); especially in squamous non-small cell lung cancer (NSCLC). Hence, we conducted a phase 3 randomized non-infe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:EClinicalMedicine
Päätekijät: Patil, Vijay, Noronha, Vanita, Joshi, Amit, Chougule, Anuradha, Kannan, Sadhana, Bhattacharjee, Atanu, Goud, Supriya, More, Sucheta, Chandrasekharan, Arun, Menon, Nandini, Srinivas, Sujay, Vallathol, Dilip Harindran, Dsouza, Hollis, Majumdar, Swaratika, Das, Sudeep, Zawar, Abhinav, Khaddar, Satvik, Kumar, Amit, Singh, Gunjesh, Kumar, Kanteti Aditya Pavan, Ravind, Rahul, Trivedi, Vaishakhi, Behel, Vichitra, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2019
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510888/
https://ncbi.nlm.nih.gov/pubmed/31143878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2019.03.011
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia